IMITREX Drug Patent Profile
✉ Email this page to a colleague
When do Imitrex patents expire, and what generic alternatives are available?
Imitrex is a drug marketed by Glaxosmithkline and is included in three NDAs.
The generic ingredient in IMITREX is sumatriptan. There are twenty-four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the sumatriptan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Imitrex
A generic version of IMITREX was approved as sumatriptan by LANNETT CO INC on February 19th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IMITREX?
- What are the global sales for IMITREX?
- What is Average Wholesale Price for IMITREX?
Summary for IMITREX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 184 |
Clinical Trials: | 23 |
Patent Applications: | 5,711 |
Drug Prices: | Drug price information for IMITREX |
Drug Sales Revenues: | Drug sales revenues for IMITREX |
What excipients (inactive ingredients) are in IMITREX? | IMITREX excipients list |
DailyMed Link: | IMITREX at DailyMed |
Recent Clinical Trials for IMITREX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kimberly-Clark Corporation | Phase 1 |
CoLucid Pharmaceuticals | Phase 1 |
Eli Lilly and Company | Phase 1 |
Pharmacology for IMITREX
Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
US Patents and Regulatory Information for IMITREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | IMITREX | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 020080-001 | Dec 28, 1992 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Glaxosmithkline | IMITREX | sumatriptan succinate | TABLET;ORAL | 020132-001 | Jun 1, 1995 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Glaxosmithkline | IMITREX | sumatriptan | SPRAY;NASAL | 020626-003 | Aug 26, 1997 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for IMITREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | IMITREX | sumatriptan succinate | TABLET;ORAL | 020132-002 | Jun 1, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | IMITREX | sumatriptan | SPRAY;NASAL | 020626-003 | Aug 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | IMITREX | sumatriptan | SPRAY;NASAL | 020626-001 | Aug 26, 1997 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for IMITREX
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Galpharm Healthcare Ltd. | Sumatriptan Galpharm | sumatriptan | EMEA/H/C/002140 |
Refused | yes | no | no | 2012-02-09 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for IMITREX
See the table below for patents covering IMITREX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 8601880 | ⤷ Sign Up | |
Singapore | 169294 | ⤷ Sign Up | |
Sweden | 8303208 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |